Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shen Long Decoction (参龙煎剂) is a Traditional Chinese Medicine (TCM) compound formula developed by the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine for the treatment of idiopathic pulmonary fibrosis (IPF). Administered as oral granules, the decoction is formulated based on the TCM theory of "collateral disease" (络病), aiming to tonify qi, activate blood circulation, and resolve stasis to treat "lung atrophy" (肺痿). Clinical studies, such as trial ChiCTR-INR-17013653, evaluate its efficacy in improving lung function (e.g., FVC, DLCO), clinical symptoms, and quality of life in IPF patients compared to placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shen Long Decoction.